Experimental Alzheimer's Drug Shows Promise in Delaying Symptoms
Scientists report that long-term use of gantenerumab might prevent cognitive decline in people with genetic predisposition to early-onset Alzheimer's.
Archive context
Older archive item. Useful for background and entity history, but not a fresh market-moving signal.
Why this matters
This cryptocurrency story adds another data point to the current market tape and is useful when read alongside nearby source coverage.
Original source
Read on DecryptRelated market context
Cipher Mining Expands AI Data Center Push With ERCOT Capacity And Long-Term Lease
TL;DR Cipher Mining disclosed conditional ERCOT interconnection capacity for up to 300 MW. The company also reported a 15-year hyp...
2 key economic reports threaten Bitcoin’s $80k rally as BTC price model predicts $95k incoming
Bitcoin entered this week (Sept. 21–27) above $80,000, but Friday's update on Americans' inflation expectations could test whether...
Galaxy reports 40% drop in crypto lending from peak as market enters orderly deleveraging phase
The gradual decline in crypto lending suggests a maturing market, fostering stability and resilience, crucial for long-term indust...
Feds Probing Binance Over Iran’s Bitcoin Use: Report
Bitcoin Magazine Feds Probing Binance Over Iran’s Bitcoin Use: Report Federal prosecutors — including the U.S. Department of Justi...
United Nations highlights Bitcoin’s promise at digital cooperation event
The UN's focus on Bitcoin as digital infrastructure could empower developing nations, fostering economic independence and sustaina...
Glassnode reports shift from Bitcoin to altcoin season amid broader rally
The shift to altcoin season suggests a diversification trend, but low leverage indicates cautious market sentiment and potential v...